Last reviewed · How we verify
Permitted DMARDs
DMARDs (Disease-Modifying Antirheumatic Drugs) suppress immune system activity to reduce inflammation and slow progression of autoimmune diseases.
DMARDs (Disease-Modifying Antirheumatic Drugs) suppress immune system activity to reduce inflammation and slow progression of autoimmune diseases. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions.
At a glance
| Generic name | Permitted DMARDs |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Disease-Modifying Antirheumatic Drug (DMARD) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
DMARDs work through various mechanisms including inhibition of T-cell activation, B-cell suppression, and reduction of pro-inflammatory cytokines. By modulating immune responses, they prevent joint damage and systemic inflammation characteristic of rheumatoid arthritis and other autoimmune conditions. The class includes both conventional synthetic DMARDs (csDMARDs) and biologic DMARDs (bDMARDs).
Approved indications
- Rheumatoid arthritis
- Other autoimmune inflammatory conditions
Common side effects
- Infection (including serious infections)
- Hepatotoxicity
- Bone marrow suppression
- Gastrointestinal disturbances
- Rash
Key clinical trials
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment (PHASE3)
- A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent (PHASE3)
- A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis (PHASE3)
- A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (PHASE3)
- A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis (PHASE3)
- A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Permitted DMARDs CI brief — competitive landscape report
- Permitted DMARDs updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI